existing approved firm faced cited alone firms partner either hit ireland analysts initiation accounts bankruptcy likely reserves receive become believed last competition price licensing monday end phytopharm availability taking pence evaluate fold group understand use cases based avonex biogen boost new hunter treated patients provide since leukoencephalopathy would rebuilding suspended level clinical evaluations product opportunity increasing expected pull case value ms stockbrokers increased fell raise deal tysabri progressive plunged took companies japan two goodbody shares pharmaceutical world yamanouchi ian closed statement agreement future irish idec rivals finished trials company uk pml growth central dublin november mark lost widely work set elan used treatment also rare experimental close drug disease condition better reports sclerosis shed sales outcome us dosing inquiry tipped multiple said investigators patient possible york brought alzheimer suspension risk involved experts question cash commercial almost questions action nervous death multifocal determine leading consult system prompting four exchange biggest stock suspected share london year